Compare Stocks → 3 Dirt-Cheap Stocks You Can’t Afford to Ignore (From TradingTips) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ELEV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeELEVElevation Oncology$3.69-3.1%$4.21$0.36▼$5.89$201.62M1.522.21 million shs313,445 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceELEVElevation Oncology+2.14%+2.14%-5.93%+41.11%+22.90%Tech GIANT’s Plans to Revolutionize Crypto… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationELEVElevation Oncology1.3634 of 5 stars3.52.00.00.00.61.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceELEVElevation Oncology3.00Buy$7.40100.54% UpsideCurrent Analyst RatingsLatest ELEV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2024ELEVElevation OncologyStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$8.005/3/2024ELEVElevation OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.004/9/2024ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/7/2024ELEVElevation OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$7.003/7/2024ELEVElevation OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$5.00 ➝ $8.003/7/2024ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.003/1/2024ELEVElevation OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$7.00(Data available from 5/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookELEVElevation OncologyN/AN/AN/AN/A$1.39 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateELEVElevation Oncology-$45.70M-$1.04N/AN/AN/AN/A-59.35%-38.54%8/1/2024 (Estimated)Latest ELEV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/2/2024Q1 2024ELEVElevation Oncology-$0.21-$0.23-$0.02-$0.23N/AN/A3/6/2024Q4 2023ELEVElevation Oncology-$0.21-$0.19+$0.02-$0.19N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthELEVElevation OncologyN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioELEVElevation Oncology0.4146.2246.22OwnershipInstitutional OwnershipCompanyInstitutional OwnershipELEVElevation Oncology83.70%Insider OwnershipCompanyInsider OwnershipELEVElevation Oncology8.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableELEVElevation Oncology2954.64 million50.21 millionOptionableELEV HeadlinesRecent News About These CompaniesMay 17, 2024 | americanbankingnews.comElevation Oncology, Inc. (NASDAQ:ELEV) Receives $7.40 Average Target Price from AnalystsMay 16, 2024 | americanbankingnews.comElevation Oncology (NASDAQ:ELEV) Now Covered by StephensMay 14, 2024 | msn.comStephens & Co. Initiates Coverage of Elevation Oncology (ELEV) with Overweight RecommendationMay 14, 2024 | marketbeat.comElevation Oncology, Inc. (NASDAQ:ELEV) Receives Average Rating of "Buy" from AnalystsMay 14, 2024 | marketbeat.comElevation Oncology (NASDAQ:ELEV) Coverage Initiated by Analysts at StephensMay 13, 2024 | bovnews.comInvesting in Elevation Oncology Inc (ELEV) Stock: MethodologyMay 7, 2024 | prnewswire.comElevation Oncology to Present at the Citizens JMP Life Sciences ConferenceMay 4, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Elevation Oncology (ELEV), Moderna (MRNA)May 3, 2024 | marketbeat.comElevation Oncology (NASDAQ:ELEV) Given "Outperform" Rating at WedbushMay 2, 2024 | markets.businessinsider.comHint Health Announces 8th Annual Hint Summit, the Leading DPC Innovation ConferenceMay 2, 2024 | msn.comElevation Oncology GAAP EPS of -$0.23May 2, 2024 | marketwatch.comElevation Oncology Shares Swing to 5% Gain After Extending Cash RunwayMay 2, 2024 | msn.comELEV Stock Earnings: Elevation Oncology Misses EPS for Q1 2024May 2, 2024 | prnewswire.comElevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business AchievementsApril 30, 2024 | medicalxpress.comCabozantinib promising for advanced adrenocortical carcinomaApril 26, 2024 | finance.yahoo.comClariane: First Quarter 2024 RevenueApril 26, 2024 | medicaldialogues.inIntravitreal dexamethasone for macular edema may increase Intraocular Pressure: StudyApril 22, 2024 | seekingalpha.comElevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade)April 12, 2024 | cancertherapyadvisor.comDoes Fracking Cause Cancer?April 12, 2024 | biospace.comAACR, Cancer Treatment and the Promise of Antibody-Drug ConjugatesApril 10, 2024 | msn.comBiologic drug-device combination immunotherapy for metastatic prostate cancer patientsNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsApril 26, 2024 3:21 AMView Stock market today: Alphabet and Microsoft help Wall Street clinch its best week in nearly 6 monthsSeagate Technology Warns Cloud Demand is Heating Up April 30, 2024 10:10 AMView Seagate Technology Warns Cloud Demand is Heating Up Pinterest Prospers From AI Boosting Shop-Ability and RelevanceMay 7, 2024 12:07 PMView Pinterest Prospers From AI Boosting Shop-Ability and RelevanceAll HeadlinesCompany DescriptionsElevation OncologyNASDAQ:ELEVElevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
